0.5872 USD
+0.01 (+1.29%)
0.59 USD
+0 (+0.48%)
We assign a fundamental rating of 3 out of 10 to HBIO. HBIO was compared to 57 industry peers in the Life Sciences Tools & Services industry. HBIO has a bad profitability rating. Also its financial health evaluation is rather negative. HBIO is valued quite cheap, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year HBIO was profitable.
- HBIO had a positive operating cash flow in the past year.
- HBIO had negative earnings in each of the past 5 years.
- In the past 5 years HBIO always reported a positive cash flow from operatings.
1.2 Ratios
- With a Return On Assets value of -69.03%, HBIO is not doing good in the industry: 89.47% of the companies in the same industry are doing better.
- With a Return On Equity value of -382.68%, HBIO is not doing good in the industry: 87.72% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.03% | ||
| ROE | -382.68% | ||
| ROIC | N/A |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- HBIO has a better Gross Margin (56.94%) than 71.93% of its industry peers.
- In the last couple of years the Gross Margin of HBIO has remained more or less at the same level.
- HBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
2. Health
2.1 Basic Checks
- HBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, HBIO has more shares outstanding
- The number of shares outstanding for HBIO has been increased compared to 5 years ago.
- HBIO has a worse debt/assets ratio than last year.
2.2 Solvency
- HBIO has an Altman-Z score of -2.69. This is a bad value and indicates that HBIO is not financially healthy and even has some risk of bankruptcy.
- HBIO has a worse Altman-Z score (-2.69) than 82.46% of its industry peers.
- HBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 4.98 | ||
| Altman-Z | -2.69 |
ROIC/WACCN/A
WACC10.62%
2.3 Liquidity
- A Current Ratio of 0.81 indicates that HBIO may have some problems paying its short term obligations.
- Looking at the Current ratio, with a value of 0.81, HBIO is doing worse than 91.23% of the companies in the same industry.
- HBIO has a Quick Ratio of 0.81. This is a bad value and indicates that HBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 0.41, HBIO is doing worse than 94.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.41 |
3. Growth
3.1 Past
- The earnings per share for HBIO have decreased by 0.00% in the last year.
- HBIO shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -19.73% yearly.
- Looking at the last year, HBIO shows a very negative growth in Revenue. The Revenue has decreased by -10.60% in the last year.
- HBIO shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.12% yearly.
EPS 1Y (TTM)0%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%100%
Revenue 1Y (TTM)-10.6%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-6.28%
3.2 Future
- The Earnings Per Share is expected to grow by 27.08% on average over the next years. This is a very strong growth
- Based on estimates for the next years, HBIO will show a decrease in Revenue. The Revenue will decrease by -0.88% on average per year.
EPS Next Y-49%
EPS Next 2Y27.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.37%
Revenue Next 2Y-0.88%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 14.68, the valuation of HBIO can be described as correct.
- 94.74% of the companies in the same industry are more expensive than HBIO, based on the Price/Earnings ratio.
- HBIO is valuated rather cheaply when we compare the Price/Earnings ratio to 27.47, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 6.06 indicates a rather cheap valuation of HBIO.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of HBIO indicates a rather cheap valuation: HBIO is cheaper than 100.00% of the companies listed in the same industry.
- HBIO's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.26.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.68 | ||
| Fwd PE | 6.06 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, HBIO is valued cheaply inside the industry as 94.74% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, HBIO is valued cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.84 | ||
| EV/EBITDA | 12 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as HBIO's earnings are expected to grow with 27.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.08%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- HBIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
0.5872
+0.01 (+1.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-10 2026-03-10/amc
Inst Owners48.8%
Inst Owner Change0%
Ins Owners3.96%
Ins Owner Change9.78%
Market Cap26.18M
Revenue(TTM)87.37M
Net Income(TTM)-53.84M
Analysts80
Price Target2.04 (247.41%)
Short Float %1.47%
Short Ratio0.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-49.02%
Min EPS beat(2)-100%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)-1.23%
Min EPS beat(4)-100%
Max EPS beat(4)75.49%
EPS beat(8)3
Avg EPS beat(8)-39.49%
EPS beat(12)5
Avg EPS beat(12)-32.85%
EPS beat(16)5
Avg EPS beat(16)-35.95%
Revenue beat(2)1
Avg Revenue beat(2)-0.39%
Min Revenue beat(2)-1.72%
Max Revenue beat(2)0.94%
Revenue beat(4)2
Avg Revenue beat(4)2.52%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)11.18%
Revenue beat(8)2
Avg Revenue beat(8)-3.88%
Revenue beat(12)3
Avg Revenue beat(12)-4.45%
Revenue beat(16)3
Avg Revenue beat(16)-4.48%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.5%
EPS NY rev (1m)0%
EPS NY rev (3m)20%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.68 | ||
| Fwd PE | 6.06 | ||
| P/S | 0.3 | ||
| P/FCF | 3.84 | ||
| P/OCF | 3.06 | ||
| P/B | 1.86 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12 |
EPS(TTM)0.04
EY6.81%
EPS(NY)0.1
Fwd EY16.5%
FCF(TTM)0.15
FCFY26.05%
OCF(TTM)0.19
OCFY32.66%
SpS1.96
BVpS0.32
TBVpS-0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.53
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.03% | ||
| ROE | -382.68% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.94% | ||
| FCFM | 7.81% |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
F-Score4
Asset Turnover1.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 4.98 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 27.22% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 193.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.41 | ||
| Altman-Z | -2.69 |
F-Score4
WACC10.62%
ROIC/WACCN/A
Cap/Depr(3y)33.21%
Cap/Depr(5y)26.48%
Cap/Sales(3y)2.31%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%100%
EPS Next Y-49%
EPS Next 2Y27.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-10.6%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-6.28%
Revenue Next Year-8.37%
Revenue Next 2Y-0.88%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y63.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5166.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.1%
OCF growth 3Y4.55%
OCF growth 5Y-29.12%
HARVARD BIOSCIENCE INC / HBIO FAQ
What is the ChartMill fundamental rating of HARVARD BIOSCIENCE INC (HBIO) stock?
ChartMill assigns a fundamental rating of 3 / 10 to HBIO.
Can you provide the valuation status for HARVARD BIOSCIENCE INC?
ChartMill assigns a valuation rating of 7 / 10 to HARVARD BIOSCIENCE INC (HBIO). This can be considered as Undervalued.
Can you provide the profitability details for HARVARD BIOSCIENCE INC?
HARVARD BIOSCIENCE INC (HBIO) has a profitability rating of 2 / 10.
Can you provide the financial health for HBIO stock?
The financial health rating of HARVARD BIOSCIENCE INC (HBIO) is 3 / 10.